Calidi Biotherapeutics Stock Quote CLDI - Stock Price, News, Charts, Message Board, Trades

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Premium

Current Price

1.21

Bid

Ask

Volume

72,869

1.15 Day's Range 1.235

0.96 52 Week Range 30.60

Market Cap

11.96M

Previous Close

1.19

Open

1.22

Last Trade

100

1.21

Last Trade Time

11:28:39

Financial Volume

$ 86,718

VWAP

1.1901

Average Volume (3m)

136,567

Shares Outstanding

9,884,153

Dividend Yield

PE Ratio

-0.41

Earnings Per Share (EPS)

-2.96

Revenue

Net Profit

-29.22M

The investment seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the FLAGLSX-Forensic Accounting Long-Short Index. The investment seeks to provide investment results that, before fees and expenses, correspond generally to the price and yield performance of the FLAGLSX-Forensic Accounting Long-Short Index.

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.calidibio.com

Headquarters

Wilmington, Delaware, USA

Founded

Calidi Biotherapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the American Stock Exchange with ticker CLDI. The last closing price for Calidi Biotherapeutics was $1.19. Over the last year, Calidi Biotherapeutics shares have traded in a share price range of $ 0.96 to $ 30.60.

Calidi Biotherapeutics currently has 9,884,153 shares outstanding. The market capitalization of Calidi Biotherapeutics is $11.76 million. Calidi Biotherapeutics has a price to earnings ratio (PE ratio) of -0.41.

Calidi Biotherapeutics Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma

Trial will evaluate multiple doses of CLD-101 for the treatment of newly diagnosed high-grade glioma CLD-101 is Calidi’s novel allogeneic immunotherapy utilizing neural stem cells to deliver...

Calidi Biotherapeutics Reports Second Quarter 2024 Operating and Financial Results

Launched Nova Cell subsidiary with $2 million investment from Dr. Ronald Rigor to advance Calidi’s Adult Adipose Allogeneic (AAA) stem cell innovative programs Strengthened team with the...

Calidi Biotherapeutics Announces Launch of Nova Cell Subsidiary and $3 Million Aggregate Investment from Dr. Ronald Rigor

SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform

SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted...

Calidi to Effect Reverse Stock Split

Calidi common stock expected to begin trading on a 1-for-10 split adjusted basis on July 15, 2024 Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi” or “Company”), a clinical-stage...

Calidi Biotherapeutics Announces Appointment of Cancer Immunotherapy Pioneer Dr. George Peoples to Board of Directors

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or “Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the...

Calidi Biotherapeutics to Host Exclusive Live Investor Webinar and Q&A Session on June 13

Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, is pleased to...

Calidi Biotherapeutics Collaborates with SIGA Technologies to Advance Calidi’s Revolutionary RTNova Virotherapy for Lung Cancer and Metastatic Solid Tumors

Calidi’s best-in-class, novel systemic targeted virotherapy program (RTNova) aims to provide a feasible solution to target disseminated tumors with a systemic administration -- a long-pursued...

Calidi Biotherapeutics Presents CLD-101 Phase 1 Trial Update and Preclinical Data Highlighting RTNova and CLD-201 at 2024 ASCO Annual Meeting

- NeuroNova (CLD-101) Phase 1 update highlights enrollment progress, safety and feasibility in delivering up to four weekly doses of CLD-101 - Showcased preclinical data on RTNova (CLD-400...

Calidi Biotherapeutics Announces Exercise of Warrants for $2.1 Million Gross Proceeds

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	0.2	19.801980198	1.01	1.235	0.9995	131537	1.16691385	CS
4	0.1	9.00900900901	1.11	1.235	0.96	80871	1.13654262	CS
12	-0.5	-29.2397660819	1.71	1.79	0.96	136567	1.38590924	CS
26	-0.779	-39.1654097536	1.989	4.9	0.96	1015572	2.04260553	CS
52	-28.49	-95.9259259259	29.7	30.6	0.96	665407	3.37101767	CS
156	-43.89	-97.3170731707	45.1	50	0.96	610271	3.6541854	CS
260	-43.89	-97.3170731707	45.1	50	0.96	610271	3.6541854	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
VTAKCatheter Precision Inc	$ 0.9823 (122.90%)	134.1M
NFLUT Rex 2X Long NFLX Daily Target ETF	$ 27.8301 (20.11%)	25.55k
YCBDcbdMD Inc	$ 0.5099 (18.58%)	632.14k
MSTUT Rex 2X Long MSTR Daily Target ETF	$ 58.54 (16.31%)	2.52M
LEUCentrus Energy Corporation	$ 92.755 (14.44%)	1.27M
MSTZT Rex 2X Inverse MSTR Daily Target ETF	$ 7.77 (-15.73%)	1.24M
YANGDirexion Daily FTSE China Bear 3X Shares New	$ 3.455 (-13.19%)	40.58M
FXPProShares UltraShort FTSE China 50	$ 17.55 (-8.97%)	19.21k
JDSTDirexion Daily Junior Gold Miners Index Bear 2X Share	$ 21.99 (-7.68%)	657.22k
KNWKnow Labs Inc	$ 0.1921 (-7.64%)	619.15k
VTAKCatheter Precision Inc	$ 0.9823 (122.90%)	134.1M
YANGDirexion Daily FTSE China Bear 3X Shares New	$ 3.455 (-13.19%)	40.58M
FXIiShares China Large Cap	$ 32.215 (4.42%)	28.23M
SOXLDirexion Daily Semiconductor Bull 3X Shares	$ 35.6501 (1.25%)	27.86M
SOXSDirexion Daily Semiconductor Bear 3X Shares New	$ 20.01 (-0.99%)	19.97M